{{Use mdy dates|date=September 2010}}
{{Infobox company
|name       =  Acorda Therapeutics Inc.
|logo       = [[File:Acorda-therapeutics-inc-logo.PNG|220px|Acorda Therapeutics]]
|caption    = 
|type       = [[Public company|Public]]  
|traded_as  = {{NASDAQ|ACOR}} {{FWB|CDG}}
|genre      = 
|fate       = 
|predecessor  = 
|successor  = 
|foundation  =  {{Start date|1995}}<ref name="Acorda FAQ">[http://phx.corporate-ir.net/phoenix.zhtml?c=194451&p=irol-faq Acorda FAQ]</ref>
|founder    =  Ron Cohen
|defunct    = 
|location_city  =  [[Ardsley, New York]]
|location_country  =  [[United States]]
|location  = 
|locations  = 
|area_served  = 
|key_people  =  Ron Cohen<br />Andrew R. Blight
|industry  =  [[Health care]]<br/>[[Biotechnology]]
|products  =  [[Tizanidine|Zanaflex]]<br />[[4-Aminopyridine|Ampyra]]
|production  = 
|services  = 
| revenue  =  {{increase}} [[United States Dollar|US$]]292.2 Million <small>(''FY 2011'')</small><ref name="Acorda-Therapeutics-2011-10-K">{{cite web  | url =http://pdf.secdatabase.com/2842/0001008848-12-000015.pdf | title = Acorda Therapeutics 2011 Annual Report - Form 10-K - February 28, 2012. | publisher = secdatabase.com | accessdate = 2012-05-16}}</ref>
| operating_income  =  {{profit}} [[United States Dollar|US$]]35.1 Million <small>(''FY 2011'')</small><ref name="Acorda-Therapeutics-2011-10-K" />
| net_income      =  {{profit}} [[United States Dollar|US$]]30.6 Million <small>(''FY 2011'')</small><ref name="Acorda-Therapeutics-2011-10-K" />
| assets      =  {{increase}} [[United States dollar|US$]]379.5 Million <small>(''FY 2011'')</small><ref name="Acorda-Therapeutics-2011-10-K" />
| equity      =  {{increase}} [[United States dollar|US$]]205.2 Million <small>(''FY 2011'')</small><ref name="Acorda-Therapeutics-2011-10-K" />
|owner  = 
|num_employees  = 328 (February, 2012) <ref name="Acorda-Therapeutics-2011-10-K" />
|parent  = 
|divisions  = 
|subsid  = 
|homepage  =  [http://www.acorda.com/ Acorda.com]
|footnotes  = 
|intl  = 
}}
'''Acorda Therapeutics''' is a [[biotechnology]] company based in [[Ardsley, New York]]. Acorda Therapeutics develops drugs to improve therapies that improve neurological function in people with [[multiple sclerosis]], [[spinal cord injury]] and other disorders of the [[central nervous system]].<ref name="Acorda 2008 FORM 10-K">[http://media.corporate-ir.net/media_files/IROL/19/194451/2008-annualreport/pdf/acorda-2008-10-k.pdf Acorda 2008 10-K Annual report]</ref> Acorda manufactures and markets the drugs '''[[Tizanidine|Zanaflex]]''' and '''[[4-Aminopyridine|Ampyra]]''' in the United States.

==History==
{{Empty section|date=January 2010}}

==Corporate governance==
{{As of|2008|12|31|df=US}} the members of the [[board of directors]] of Acorda Therapeutics are:<ref>[http://phx.corporate-ir.net/phoenix.zhtml?c=194451&p=irol-govboard Acorda Board of Directors]</ref> Ron Cohen, Barry Greene, John Kelley, Sandra Panem, Lorin J. Randall, Steven M. Rauscher, Ian F. Smith, and Wise Young.

==Products==

===Products on the market===
{{Expand section|date=January 2010}}
* [[Tizanidine|Zanaflex]]
* [[4-Aminopyridine|Ampyra]]

===Products under development===
{{Empty section|date=January 2010}}

==References==
{{Reflist|2}}

==External links==
{{Portal|Companies}}

* {{Official website|http://www.acorda.com/}}
* [http://topics.nytimes.com/top/news/business/companies/acorda-therapeutics-inc/index.html Acorda Therapeutics Inc.] ''[[The New York Times]]''
* [http://www.hoovers.com/global/cobrands/nasdaq/factsheet.xhtml?ID=121830 Acorda Therapeutics Inc.]
[[Hoover's]]
{{Pharmaceutical companies of the United States}}

[[Category:Biotechnology companies of the United States]]
[[Category:Pharmaceutical companies of the United States]]
[[Category:Companies established in 1995]]
[[Category:Companies based in New York]]
[[Category:Companies in the NASDAQ Biotechnology Index]]


{{Med-company-stub}}
{{Biotech-stub}}
{{US-company-stub}}